Pre-Made Modakafusp Alfa Biosimilar, Fusion Protein targeting CD38 fused with human IFNA2 (interferon alpha 2) *b (R46,H57) 24-188: Recombinant therapeutic protein targeting ADPRC 1/ADPRC1 for drug discovery and mechanism of action (MOA) research

Pre-Made Modakafusp Alfa Biosimilar, Fusion Protein targeting CD38 fused with human IFNA2 (interferon alpha 2) *b (R46,H57) 24-188: Recombinant therapeutic protein targeting ADPRC 1/ADPRC1 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Modakafusp alfa is a first-in-class immunocytokine designed to deliver interferon alpha-2b (IFN¦Á2b) to CD38+ cells. It consists of two attenuated IFN¦Á2b molecules genetically fused to the Fc portion of a humanized, anti-CD38, IgG4 monoclonal antibody (mAb). The specificity for CD38 and reduced IFN receptor binding affinity of the attenuated IFN¦Á2b molecules significantly reduces the potential for off-target binding and toxicity. Modakafusp alfa is a novel candidate for the treatment of relapsed/refractory multiple myeloma.